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SurvivalType I programmed cell death (PCD) or apoptosis is critical for cellular self-destruction for a variety of
processes such as development or the prevention of oncogenic transformation. Alternative forms, including
type II (autophagy) and type III (necrotic) represent the other major types of PCD that also serve to trigger cell
death. PCD must be tightly controlled since disregulated cell death is involved in the development of a large
number of different pathologies. To counter the multitude of processes that are capable of triggering death,
cells have devised a large number of cellular processes that serve to prevent inappropriate or premature PCD.
These cell survival strategies involve a myriad of coordinated and systematic physiological and genetic
changes that serve to ward off death. Here we will discuss the different strategies that are used to prevent cell
death and focus on illustrating that although anti-apoptosis and cellular survival serve to counteract PCD, they
are nevertheless mechanistically distinct from the processes that regulate cell death.; fax: +1 613 542 9489.
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ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction: an overview of programmed cell death (PCD)
Apoptotic cell death is a genetically programmed mechanism(s)
that allows the cell to commit suicide [1–4]. Apoptosis is critically
important for the survival of multicellular organisms by getting rid of
damaged or infected cells that may interfere with normal function
[5,6]. The extrinsic and intrinsic pathways represent the two major
well-studied apoptotic processes [2,7]. The extrinsic pathway is
mediated by a sub-group of Tumor Necrosis Factor receptors (TNFR)
superfamily that includes TNFR, Fas and TRAIL. Activation of these so-
called death receptors leads to the recruitment and activation of
initiator caspases such as caspases 8 and 10 (Fig. 1). The process
involves the formation and activation of complexes such as the death
inducing signaling complex (DISC). This leads to the activation of an
effector caspase, typically caspase 3. The active caspase 3 is
responsible for the cleavage of a number of so-called death substrates
that lead to the well-known characteristic hallmarks of an apoptotic
cell including DNA fragmentation, nuclear fragmentation, membrane
blebbing and other morphological and biochemical changes. More
recent evidence suggests even greater complexity and diversity in the
extrinsic pathways that also involves the cross-activation of other
apoptotic pathways such as the intrinsic apoptotic as well as necrotic
sub-pathways [2,8] (see also below).
The cell autonomous or intrinsic pathway is largely centered
around and/or regulated by themitochondria [9–11]. Themost widely
studied form of intrinsic apoptosis is initiated by the stress-mediatedrelease of cytochrome c from the mitochondria that results in the
formation of the apoptosome (Fig. 1). The apoptosome then activates
initiator caspase, typically caspase 9, which leads to the activation of
the executioner caspase 3. This leads to the same type of apoptotic
response as observed for the extrinsic pathway. In response to
apoptotic stimuli, pro-apoptotic members of the Bcl-2 protein family
(Bax and Bak) become activated and act on the mitochondria to
induce the release of cytochrome c. Other pro-apoptotic proteins are
also released by the mitochondria including Smac/Diablo (Second
Mitochondrial derived activator of Caspase/Direct IAP-Binding protein
with a LOw pI), the serine protease Omi/HtrA2, endonuclease G
(EndoG) and apoptosis inducing factor (AIF) [12–14]. These later
examples as well as a number of others described later, clearly
demonstrates the central role of the mitochondria in the highly
regulated and complex process of many forms of programmed cell
death (PCD) [9,11,15–17]. As mentioned above, activation of the
mitochondrial pathway can also occur following the activation of the
extrinsic pathway. This has been shown to occur via the caspase
8 cleavage of the pro-apoptotic Bcl-2 member Bid to its activated tBid
form [10]. This relatively simple example of cross-talk between
apparently distinct apoptotic pathways further serves to illustrate a
common theme of the complex interrelationships that is now
commonly observed in the different processes involved in regulating
cell death (see also below) [8,13,17,18].
In addition to type I or apoptotic cell death, at least two other
major forms of programmed cell death exist [2,4,19]. Autophagy has
received considerable more attention in recent years because of the
dual and somewhat contradictory roles it plays in mediating decisions
between life and death. Autophagy is an important multifunctional
process, which cells use to recycle cellular constituents, a process that
Fig. 1. Schematic representation of the cellular pathways of apoptosis or type II programmed cell death (PCD) with an emphasis on the mechanisms that promote survival. A variety
of central players are illustrated including different membrane proteins imbedded into the cell membrane, the mitochondria is shown as a orange oval while an empty oval depicts
the nucleus. Cell death and anti-apoptotic genes are respectively shown as black and blue boxes. There are two forms of type I PCD named intrinsic and extrinsic. The intrinsic form is
triggered by a variety of stimuli including a number of stresses. The stresses lead to activation of Bax (via activation of Bcl-2 BH3 only proteins), the production of Reactive Oxygen
Species (ROS) and ceramide that serve as second messengers that converge on the mitochondria. This leads to the release of apoptogenic factors including cytochrome c,
endonuclease G (Endo G) and Apoptosis Inducing Factor (AIF). Cytochrome c combines with pro-caspase 9, APAF-1 and dATP to form the apoptosome that leads to cell death via the
activation of a caspase cascade. Extrinsic apoptosis is also due to the activation of the same caspase cascade as the intrinsic form but in this case, it is activated by cytokine type
receptors for TNF, TRAIL and FasL. Cross-talk between the extrinsic and intrinsic forms occurs via the extrinsic mediated activation of the BH3 only Bid protein into its tBid active
form. A variety of proteins serve to antagonize type I PCD including Inhibitors of Apoptosis Proteins (IAPs), FLIPs, Faim3 and the anti-apoptotic Bcl-2 proteins of which Bcl-2 is the
most common. The color blue is used to depict anti-apoptotic processes while squares at the end of lines indicate inhibition.
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ability to recycle old components into new building blocks makes
autophagy essential for survival during starvation. Studies that are
more recent have also shown that autophagy is activated by a
multitude of stresses and it is critical for surviving these stresses.
Autophagy is reported to be so powerful and ubiquitous that it is likely
the most impressive weapon in the cell's anti-death arsenal [22].
Almost paradoxically, autophagy is alsowell known as type II PCD that
may be described as a type of caspase independent cell death that is
associated with the presence of autophagosomes [23–27].
Necrosis or type III cell death was originally thought to be the
catastrophic form of death [25]. More recent evidence, including the
fact that there are genetic inhibitors of some forms of necrosis,
suggests that subforms of necrotic death may have a genetic
component. For example, in addition to activating apoptosis,
stimulation of TNF-α receptors can also lead to the induction of a
programmed from of necrosis called necroptosis [28]. Receptor
mediated activation of Receptor Interacting Protein 1 (RIP1) kinase
and formation of a necroptosis inducing active complex consisting of
RIP1 and RIP3 has been implicated. Thus it also functions as a form of
PCD that occurs under certain pathological situations (i.e. in the heart
or brain during ischemia) [29,30]. The lysosome itself may directly
participate in type III PCD by releasing lysosomal components such as
proteases that may themselves trigger cell death [31]. Other
organelles like the endoplasmic reticulum (ER) may have more
complex roles since it may be involved in triggering type III or type I
PCD [32,33]. More specialized or alternative forms of cell death
including anoikis (the PCD that occurs when cells lose anchorage,
contact with their substratum or neighboring cells) and pyroptosis
(infection mediated cell death) are also important under some
conditions or in some cell types [34–37]. The diversity in the
processes involved in inducing PCD belies the complexity and a
large number of different proteins that can prevent the different
“specialized” forms of apoptosis [38–41].
Although many excellent global reviews on cell death have been
presented there have been comparatively very few attempts at
providing a comprehensive review on the processes involved in
promoting cell survival. Given the overwhelming evidence that anti-
apoptosis is a global cellular process that is complimentary but
distinct from apoptosis (think kinases versus phosphatases), we have
attempted here to provide a global type framework for anti-apoptosis
and cell survival processes. The topic is huge and we apologize for the
omission of a large number of references that we could not include
here due to space limitations. We refer the reader to a number of
excellent reviews that provide more in depth analysis of some of the
subtopics within the cell survival ﬁeld [4,38,42–55].
2. Regulation of apoptosis
2.1. Induction of apoptosis
All metazoan as well as all protozoan cells examined have the
ability to undergo apoptosis when conditions are appropriate [16,56–
59]. The sacriﬁce of individual cells that are defective, damaged or
otherwise a potential threat to the integrity of the whole organism, or
to the colony in the case of protozoans, is thought to be an important
survival mechanism. Apoptosis can be induced by a wide range of
stimuli that are encountered during normal or pathophysiological
processes [3,60]. For example death receptor agonists may be used by
immune cells to trigger apoptosis in speciﬁc populations of defective
cells. In contrast, increased neurohormonal stimulation including
elevated levels of agonists for adrenergic and Angiotensin II (AngII) G-
Protein Coupled Receptors (GPCR) that are observed in patients with
chronic heart failure also trigger cell death in cardiac and skeletal
muscle cells [61–63]. In addition to speciﬁc stimuli such as receptor
agonists, other stimuli including amultitude of other extracellular andintracellular stresses that can serve to induce the intrinsic apoptotic
pathway [3,57]. These include a large variety of different physico-
chemical stresses such as chemotherapeutic agents (i.e. doxorubicin),
alterations in temperature and osmolarity, DNA damaging agents, free
radical generating compounds (i.e. H202), removal of nutrients,
oxygen or growth factors, pro-inﬂammatory cytokines as well as
normal physiological processes such as aging and development
[3,62,64–71]. Some of these as well as a number of other apoptotic
stimuli are linked to speciﬁc diseases. The pathological stimuli include
ischemia and subsequent reperfusion that is seen in heart attacks or
stroke as well as other processes including the accumulation of
misfolded ER proteins that is often seen and may be the basis for the
cell death observed in neurological diseases such as Parkinson's
[17,55,72].
The processes involved in initiating the intrinsic pro-apoptotic
cascade in response to an appropriate stress is like many processes
associated with PCD, very well studied but, still incompletely
understood (Fig. 1). What appears to be clear, at least in some cases,
is that the stress leads to activation of pro-apoptotic Bcl-2 members
like Bax or Bak [10,73–75]. Active Bax is recruited to the mitochondria
and forms pores that allow the release of pro-apoptogenic factors such
as cytochrome c, which then leads to the formation of the
apoptosome. This serves to initiate the intrinsic apoptotic signaling
cascade that involves sequential activation of both initiator and
effector caspases leading to cell death (Fig. 1). Reactive oxygen species
(ROS) also represents a major player in this process [76,77]. It should
be noted that the term ROS refers to a number of different
physiologically relevant molecules including superoxide anions
(O2 2), hydrogen peroxide (H2O2), free hydroxyl radicals (OH ), nitric
oxide (NO ) as well as some combinations of ROS (i.e., NO and O2 2)
can yield new species such as peroxynitite (ONOO−) [4,78,79].
Different stimuli will lead to the production of different ROS species
and in turn these will elicit different responses [80,81]. Its levels are
increased in response to stress likely due to increases inmitochondrial
damage. It appears to stimulate the apoptotic cascade by causing
damage to many cellular components including proteins, lipids and
the mitochondria itself which in turn likely facilitates the further
release of apoptogenic factors [77,82]. Like ROS, the sphingolipid
ceramide also plays a critical pro-apoptotic role. Although less is
known regarding ceramide, likely due in part to the technical
difﬁculties in monitoring the levels of sphingolipids, it is nevertheless
quite clear that ceramide is a ubiquitous pro-apoptotic second
messenger whose levels are elevated in response to multiple stresses
[83–85]. Ceramide has been shown to activate a variety of intracel-
lular targets but the mechanism by which it induces apoptosis is not
well known [86].
It is quite clear from the above discussion that Bax, ROS and
ceramide are important mediators of the cell death that is induced by
a variety of different stresses (Fig. 2). Quite a bit is known regarding
the regulation and the function of these factors. For example, the
source of stress-mediated increases in ROS is likely the mitochondria
or NADPH oxygenase [82]. Similarly, the stress-mediated activation of
Sphingomyelinase (SMase) which serves to produce ceramide from
sphingomyelin is likely the major source of the increase in ceramide
during stresses [83]. Although numerous models have been devel-
oped, the activation of Bax by stress activated BH3 only Bcl-2 proteins,
is the most likely scenario [74]. Ceramide, ROS and active Bax seem to
behave independently of each other since increases in any of the three
is sufﬁcient to trigger cell death. However, they are also intimately
linked such that increases in either one of the three leads to either
increased levels of the other or an increase in their ability to function.
Commonly proposed mechanisms of cross-talk between ROS and Bax
mediated apoptosis involves the convergent activation of common
pro-apoptotic proteins such as JNK kinase as well as the possibility
that proteins such as Bcl-2 have dual functions as a Bax inhibitor as
well as being able tomediate a small increase in the production of ROS
Fig. 2. Schematic representation of the processes involved in inducing stress mediated cell death and its inhibition by key anti-apoptotic proteins. The release of the apoptogenic
mitochondrial factors is mediated by the action of at least three different pro-apoptotic messengers including active Bax, Reactive Oxygen Species (ROS) and the sphingolipid
ceramide (shown as red boxes). The stress mediated activation of BH3 only Bcl-2 proteins, of mitochondria (or other ROS producing systems such as NADPH oxidase) and of
Sphingomyelinase (SMase) (all three are shown in purple boxes) respectively leads to increased levels of active Bax, ROS and ceramide. Ceramide which serves as the substrate for
SMS1, along with inactive Bax, are shown in green boxes. Anti-apoptotic genes have been identiﬁed that can prevent cell death in response to increases for all three factors (shown in
blue boxes). Bcl-2 can prevent the effects of active Bax, ROS scavenging proteins can prevent the effects of ROS and the ceramide utilizing enzyme Sphingomyelin Synthase 1 (SMS1)
can prevent the effects of ceramide. A common mechanism or target that serves to transduce stresses into the processes that activate the three different systems responsible for
increasing active Bax, ROS or ceramide is depicted by a black box. A single common target that trifurcates is envisioned due to the observations that overexpression of any one of the
three types of anti-apoptotic genes can prevent stress mediated cell death. Thus the stress mediated responses leading to death has characteristics of a linear as well as a series of
branched pathways. The insert depicts a simpliﬁed model that illustrates the concept of a linear pathway where all anti-apoptotic genes can prevent stress mediated cell death. The
cross-talk that occurs between the different branches in the pathway is extensive and can be shown to occur at many levels some of which are shown by connecting arrows. For
example, ectopic expression of active Bax leads to activation of all three branches since increases in ceramide and ROS are also observed. Further insight is provided by the
observation that overexpression of many other anti-apoptotic sequences such as the genes encoding a variety of chaperone or heat shock proteins can also prevent cell death in
response to the activation of one or all three branches of the stress pathway. An alternative scenario that is not depicted, to explain the close interrelationships between the different
processes would be a modiﬁed rheostat model. Cell death in response to stress occurs when a certain threshold concentration of pro-apoptotic second messengers is reached.
Stresses increase the concentration of many of thesemessengers while any gene or process that decreases the levels of any of the secondmessengers reduces stress and decreases the
likelihood that cell death inducing cascades are triggered.
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Thus Bcl-2 may simultaneously and independently inhibit both Bax
and serve to activate cellular defense systems. The later function was
supported by the observation that decreased Bcl-2 expression leads to
increased oxidative stress while Bcl-2 overexpression leads to
reduced oxidative stress [88,89]. An alternative scenario suggests
that ROSmay serve as a direct activator of the Bax activating BH3 Bcl-2
Bnip3 protein [90]. Further cross-talk is evident by the observations
that increases in the levels of ceramide can serve to trigger increases
in ROS while others have shown that increased ROS can increase
ceramide levels [91–93]. The ability of ceramide to assist activated Bax
in forming mitochondrial pores represents another manifestation of
the cross-talk present in the system [94]. More recently, a direct role
for the pro-apoptotic Bcl-2 protein Bak has been proposed for the
production of ceramide in response to apoptotic stimuli [95]. In spite
of this, very little is known regarding how stress is transduced into
increases in ROS, ceramide or activated Bax (Fig. 2). In fact, there is no
clear evidence to differentiate whether increases in ROS or ceramide
or the activation of Bax represent the initial event serving to trigger
stress-mediated apoptosis. Thus, the process by which stress initiates
apoptosis remains undeﬁned [13,75,94].The difﬁculty in identifying and assigning function to pro-
apoptotic factors is made easier by the identiﬁcation of anti-apoptotic
sequences that prevent the activation or promote a decrease in the
levels of ROS, active Bax or ceramide. For example, overexpression of
numerous genes encoding ROS scavengers such as glutaredoxins,
peroxiredoxin, superoxide dismutase and glutathione peroxidase, the
gene encoding the ceramide utilizing Sphingomyelin Synthase 1
(SMS1) or of the gene encoding the Bax inhibitory protein Bcl-2 can
prevent stress mediated apoptosis in many cells [10,77,96–104]. In
keeping with the intimate nature of cross talk between the three
factors, any one of the three different anti-apoptotic genes can serve
to prevent apoptosis in response to Bax, ceramide or ROS. Thus,
somewhat paradoxically, increases in the levels of activated Bax, ROS
or ceramide all can serve to activate apoptosis while individually
blocking anyone of these is sufﬁcient to prevent apoptosis. We have
developed a schematic depiction of the interrelationships between
the Bax, ceramide and ROS with stress and cell death (Fig. 2). In spite
of the inadequacy of the model, it is quite clear that advances in our
understanding of anti-apoptosis does lead to increases in our
understanding of the paradigms involved in the processes of
regulated cell death.
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yeast, undergo stress mediated dependant programmed cell death
(PCD) in spite of the fact they do not appear to have a Bax orthologue
[58,105]. This is evidence in support of ROS or ceramide as the central
mediator of apoptosis. Nevertheless, it should be noted that the
existence of a possible functional homologue of Bax has been
suggested by the observations that ectopically expressed mammalian
Bax and Bcl-2 appear to retain their ability to regulate apoptosis in
yeast [75]. In addition, as observed in mammalian cells, heterolo-
gously overexpressing active Bax in yeast leads to increases in stress
mediated cell death that can be blocked by simultaneously over-
expressing the Bax inhibitor Bcl-2 or genes encoding ROS scavengers
or a ceramide utilizing protein [101,106–110].
In addition to ROS and ceramide a number of other intracellular
second messengers such as calcium and the nucleotide 2′-Deoxyur-
idine 5′-Triphosphate (dUTP) have also been shown to trigger
apoptotic responses [111–114]. Although a role for dUTP in selectively
killing cells has been long ago identiﬁed in fruit ﬂy development, more
recent evidence suggests that it has a more widespread role in
initiating pro-apoptotic responses [113,115,116]. This nucleotide is
known to cause DNA damage and cell death when it is misincorpo-
rated into DNA [113,114,117]. In effect, elevated dUTP levels are
responsible for the apoptotic inducing effects of many chemothera-
peutic compounds that promote cell death at least in part by creating
nucleotide pool imbalances (i.e. thymidylate synthase inhibitors)
[113,118]. Further dUTP incorporation into the genome of virusesmay
be a common mechanism that is used by infected cells to kill viruses
or to undergo suicide [114]. Not surprisingly, many viruses encode
their own dUTPase [114]. Once again the importance of these second
messengers is highlighted by the observations that calcium binding
proteins such as fortilin as well as the dUTP metabolizing enzyme
dUTPase are capable of preventing cell death in response to some
stresses when overexpressed in cells [111,113] (Khoury and Green-
wood, unpublished).
2.2. Negative regulation of apoptosis
Cells monitor their environment and continuously make decisions
as to whether they should continue living. When faced with a
potential apoptotic signal the cell wants to avoid triggering premature
or unneeded apoptosis all the while it wants to make sure to initiate
apoptosis if the signal is of signiﬁcant intensity. This is achieved by
balancing pro- and anti-apoptotic machineries [38,42,43]. In the lab
we can determine the maximum dosage of a stress (a combination of
time of exposure to and concentration of the agent used) that will give
rise to no death [119–121]. Hydrogen peroxide (H2O2) is a commonly
used agent to induce apoptosis and is an excellent stressor that can
serve to illustrate this point. In our hands, dose response/viability
curves using H2O2 have shown that 24 h exposure to 0.6 μM H2O2 for
C2C12 mousemyoblast cells and 4 h exposure to 0.8 mMH2O2 for wild
type yeast are the maximum dosages causing no or little cell death in
these cells. At this dosage of stress, the cells are not undergoing
apoptosis because they are actively resisting cell death. Evidence that
this must be true, is based on the observation that such mild non-
apoptotic inducing stimuli is able to induce apoptosis in cells having
reduced expression levels of a number of different genes encoding
different anti-apoptotic proteins such as the lectin galectin 3, the Bcl-2
family members Mcl-1 and Bcl-xL as well as enzymes like sphingosine
kinase-1 due to knock outs or siRNA [99,122–128]. Thus, the absence
of anti-apoptotic genes increases sensitivity to sublethal apoptosis
inducing agents. It follows that an increase in the levels of anti-
apoptotic genes leads to increased resistance to apoptotic stimuli.
Thus, the minimum dosage of a stress required to kill a cell that is
overexpressing anti-apoptotic genes is increased. This leads to the
workable deﬁnition of an anti-apoptotic gene as a sequence that
decreases or increases cell survival in response to a given dose ofstress if its levels are respectively decreased or increased
[12,38,96,99,122–141]. Genetic redundancy in different anti-apopto-
tic processes make it so that a number of genes can prevent apoptosis
when overexpressed while their loss does not enhance apoptotic
responses. An impressive number of functionally diverse genes that
behave as anti-apoptotic sequences have been reported (see Section
4.2). The number of yet to be characterized candidate anti-apoptotic
genes identiﬁed in screens or as genes that are up-regulated in
apoptotic resistant cells clearly indicates that the list is not yet
complete [142–148].
It is worthmentioning that there are three well characterized anti-
apoptotic family of proteins including FLICE-inhibitory proteins
(FLIPs), Bcl-2 and Inhibitors of Apoptosis Proteins (IAPs) that are
described in most discussions of caspase dependent apoptotic path-
ways (Fig. 1) [1,42,44]. Of great importance in the regulation of
apoptosis is the Bcl-2 Homology domain (BH) domain containing
family of proteins. This family contains both negative and positive
regulators of apoptosis with Bax being the most studied pro-apoptotic
member while Bcl-2 the most studied anti-apoptotic member [10,74].
Bcl-2 antagonizes the effects of Bax and prevents the release of
cytochrome c. Bcl-2 function is not limited to inhibiting Bax since Bcl-
2 can inhibit apoptosis in response to microinjected cytochrome c and
when overexpressed in yeast cells in spite of the fact that the yeast
genome does not encode a direct Bax orthologue [106,107,149,150].
In contrast to the intrinsic pathway, the initiation of the apoptotic
signaling cascade by the stimulation of Death receptors appears to
more closely resemble a traditional cytokine type signaling cascade
[151]. Nevertheless, this pathway is also negatively regulated in order
to prevent inappropriate cell death. FLIPs (FLICE Inhibitory Protein)
represent the most commonly examined inhibitor of the extrinsic
pathway. FLIPs contain the same DED domain as caspase 8 and can
thus compete with and prevent caspase 8 activation by interfering
with its recruitment to the activated receptor [152]. The third well-
studied class of cell survival proteins is the family of Inhibitors of
Apoptosis (IAPs). These serve to bind and inhibit both initiator and
effector caspases thus they can regulate both forms of apoptosis [153].
This functional class of protein was ﬁrst described in the genome of
baculovirus and underlines the resources placed by viruses in
controlling apoptotic responses [154].
Directly antagonizing pro-apoptotic proteins and increasing the
expression levels of anti-apoptotic genes, including genes involved in
metabolizing pro-apoptotic second messengers, are likely the most
commonly reported pro-survival strategies [4,42]. Other ways to
increase survival in response to stresses include a diversity of other
processes, some of which like the receptor mediated activation of
kinase cascades (i.e. Extracellular Regulated Kinases (Erk1/2) and Akt
kinases) are rapid since they can occur in the absence of new RNA or
protein synthesis [69]. Our understanding of the diversity of the anti-
apoptotic processes, the diversity of the anti-apoptotic genes involved
as well as the mechanisms by which some of these processes and
genes function to counteract apoptotic responses has been greatly
enhanced from the study of cells showing enhanced resistance to cell
death inducing stresses and processes.
3. Anti-apoptotic and pro-survival pathways and processes
identiﬁed in apoptotic resistant cells
Cells that show increased resistance to stress are characterized by
their requirement for higher levels of apoptotic stimuli for cell death
to be induced. A wide variety of cell types can show increased
resistance which can be induced by a wide variety of different
conditions. The ability to evade apoptosis has been shown to be
induced by a range of different alterations including physiological
changes such as the activation/up-regulation of mitogenic signaling
pathways (i.e. Erk1/2, Akt), the inactivation/downregulation of
certain apoptotic molecules (i.e. Fas receptor, Bax ) [69,130,155,156]
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and cFLIP [157,158]. Thus in the next sections we will describe
conditions that serve to render cells more resistant as well as the wide
diversity of known mechanisms that confer anti-apoptotic pheno-
types to these cells.
3.1. Pre-conditioning
Brief sub-lethal periods of stopping and re-starting blood ﬂow
(ischemia/reperfusion) are found to induce a phenotype that is
protective to the effects of longer periods of ischemia/reperfusion
[52,53,159,160]. Although this process likely occurs in all cell types, it
has been extensively studied (at least for metazoans) in the heart and
the brain, historically due to the importance that ischemic events have
in the etiology of heart attacks and strokes [52,53,159,161].
Consequently, we largely focus our discussion on these systems
since our understanding of the process of pre-condition mediated
anti-apoptosis is likely best understood in these cells. Ischemic pre-
conditioning gives rise to two temporally distinct types of protection.
Classical pre-conditioning provides a temporal window of protection
that occurs minutes after the pre-condition stimulus (which usually
consists of 3–4 short periods of ischemia/reperfusion) [52,53,160].
The protection can last up to 120 min and involves a number of
signaling proteins including the activation of multiple protein kinase
cascades such as ERK and Akt, many of which are known to have anti-
apoptotic properties [53]. In response to the same stimuli, a second
form of pre-conditioning, called late onset pre-conditioning is also
induced. This provides long-term protection that lasts 24 to 72 h after
the pre-condition stimulus [52,53,160]. This form of pre-conditioning
requires protein synthesis and involves the increased expression of a
number of genes that encode proteins such as heat shock proteins
(HSPs), anti-oxidants, ceramide utilizing enzymes, as well as a
number of other anti-apoptotic genes, many of which encode proteins
of unknown function [52,53,162]. That these genes are anti-apoptotic
is demonstrated by the fact many of them decrease ischemia/
reperfusion mediated death when overexpressed in the hearts of
transgenic mice [96,97,135,136,163]. Similarly, protection from
apoptotic stimuli is also observed when individual anti-apoptotic
genes are overexpressed in cultured cells [47]. In addition to
increasing the expression of anti-apoptotic genes, it should also be
noted, although not dwelled upon here, that the protection provided
by late onset pre-conditioning might also occur via other mechanisms
such as the decrease in the expression of pro-apoptotic genes such as
Bax.
The protective effects of ischemic/reperfusion pre-conditioning
can also be mimicked in cultured cells [119–121,164]. Thus in spite of
the availability of a number of animal models, cultured cells including
primary cultured cardiomyocytes and neurons have been extensively
used to study pre-conditioning [165–168]. Of interest here, it was
found that pre-conditioned like apoptotic resistant phenotypes are
not exclusively dependant of the use of mild ischemia/reperfusion as
the stimulus. In effect, resistance to apoptotic inducing doses of
practically any apoptotic-inducing agent is sufﬁcient to confer a
cytoprotective pre-condition like phenotype. In mammalian organ-
isms, the cytoprotective effects of pre-conditioning appears to be
mediated by the release of a number of agents including agonists for
G-protein coupled receptors (GPCRs) like adenosine, adrenergic and
opioids [49]. Although these agonists can confer cytoprotective effects
in cultured cells, their release is not responsible for mediating the
effects of all pre-conditioning agents. A wide range of different agents
and environmental stresses have been shown to induce pre-condition
like effects. Global gene expression methodologies including gene
chips, proteomics and subtractive hybridization experiments as well
as candidate gene approaches reveal that increased expression of anti-
apoptotic genes is also a common mechanism that serves to invoke
increased survival phenotypes in response to a wide variety ofdifferent pre-conditioning agents and conditions in whole animals
and in cultured cells [159]. Some examples include human ﬁbroblasts
subjected to microgravity stress on the space shuttle, cardiac cells of
mice pre-treated with hydrogen sulﬁde showed increased protection
against the stress of ischemia/reperfusion, the retina of hyperoxic and
hypoxic conditioned mice pups, the nucleus accumbens region of the
brain of rats in the early acute phase of alcohol withdrawal and
exogenously supplied ceramide to primary rat cortical neurons, the
use of heat pre-treatment to protect from stresses such as the ROS
donor hydrogen peroxide as well as the use of low sublethal levels of
the ROS donor hydrogen peroxide to protect against serum depletion
mediated apoptosis [119–121,147,167,169–172]. In addition pre-
condition like phenotypes that are at least partly dependant on the
increased expression of survival genes is a highly conserved process
that is observed in a number of different species including bacteria,
yeast and lower metazoans [162,173–175]. The similarity in the
process between metazoans and protozoans is such that many
mammalian anti-apoptotic genes can functionally serve to protect
yeast cells from stress mediated apoptosis [105,176].
Pre-conditioning mediated cytoprotection induced by sub-lethal
levels of different stresses appears to be mediated by the increased
expression of a core group of powerful anti-apoptotic genes. These
include gene encoding ROS scavengers as well as heat shock proteins
(HSPs) and other chaperones. HSPs actually represent a large number
of different proteins that belong to a number of different sub-families
[177,178]. Although originally identiﬁed as proteins whose expres-
sion are increased in response to heat stress, different HSPs are now
known to be also induced and to protect cells from a variety of
apoptotic inducing stresses as well as having functions in homeostasis
such assisting in protein folding [179]. HSPs likely protect cells by
assisting in refolding proteins denatured due to stresses as well as
assisting to target damaged proteins for degradation. The HSPA/
HSP70 sub-family, which consists of at least 13 different members, is
one of the largest and most widely studied HSPs. A number of studies
have demonstrated that overexpression of members of the HSP70
sub-family can protect cells from different apoptotic inducing stresses
[180,181]. Other anti-apoptotic functions of HSP70 and other HSPs
have been reported including preventing the release of pro-apoptotic
factors such apoptosis inducing factor (AIF) from the mitochondria
[182]. Although all HSPs are considered chaperones, there are a
number of proteins that function as chaperones without being HSPs.
Some of these chaperones with anti-apoptotic functions include
members of the Bcl-2-associated anthanogene (BAG) and clusterin
families [183,184]. Some of these proteins, like BAGs likely serve to
inhibit apoptosis by acting as co-chaperones for other proteins like
HSPs although there is recent evidence that BAGs may be cytopro-
tective by inducing autophagy (see also Section 5) [185,186]. This
belies one of the central themes of anti-apoptosis that proteins
capable of preventing or repairing stress mediated cell damage are
likely to be cytoprotective [4]. In addition to commonly up-regulated
genes, there appears to be subset of genes that are up-regulated by
speciﬁc stresses. For example, DNA damaging agents will lead to the
up-regulation of DNA repair enzymes that will then serve to protect
DNA damaged cells [81]. In the absence of DNA damage, these genes
are unlikely to be cytoprotective and thus will not be induced by
agents not damaging DNA. One somewhat surprising ﬁnding is the
observation that stresses that could be expected to illicit similar
damages on a cell, such as two different donors of reactive oxygen
species (ROS) can have signiﬁcantly dissimilar patterns of altered
gene expression [80,81]. This suggests that there is a large and
complex repertoire of stress activated cytoprotective genes that are
available for the cell faced with different stresses.
Although a number of permutations on the process of pre-
conditioning that have been described, two of these including post-
conditioning [187] and remote pre-conditioning [188,189] are worth
discussing here. As mentioned above, administration of a pre-
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tissue such as the heart will lead to cardioprotection as judged by a
decreased infarct size. Surprisingly, post-conditioning is the phenom-
ena where a pre-conditioning type stimuli administered after the
cardiac apoptotic insult will still result in the same degree of
cardioprotection. This has clinical implications since, patients are
usually seen after and not before and ischemic/reperfusion event.
Mechanistically, this suggests that anti-apoptotic processes can
override apoptotic-inducing signals even after they have been
initiated. On the other hand, remote pre-conditioning is a process
that leads to protection at sites that are distant from the site that is
subjected to a pre-condition regimen. Thus, a series of short ischemic/
reperfusion events to a limb can lead to induction of a cytoprotection
program in a remote area like the heart. This suggests that cells
undergoing pre-conditioning release a factor or factors (like receptor
agonists, as discussed above) that can diffuse and induce anti-
apoptotic effects in other cells. The clinical application of remote pre-
conditioning has shown some promise as well as some limitations
[166,189,190].
3.2. Cancer
Normal cellular homeostasis is maintained by a balance between
the processes of growth and cell death. Imbalances in either can lead
to uncontrolled cell growth and the development of cancer
[11,158,191]. Thus constitutive activation or increase of many
mitogenic proteins such as myc, src and ras or growth promoting
pathways such as mitogenic activated protein (MAP) kinases,
epidermal growth factor receptor (EGFR) and phosphatidylinositol
3-kinases (PI3K) often lead to uncontrolled growth that serves to
promote oncogenesis [69,156]. Alternatively, altered regulation of the
process of apoptosis has also been linked to all the different processes
of oncogenesis including initiation, progression and metastasis
[4,34,35,43,45]. Given that the development of an anti-apoptotic
phenotype is one of the hallmark characteristic that is required for
cells to become cancerous, our understanding of the processes that
can lead to anti-apoptosis is probably best characterized in cancer
cells [38,43,158,192,193]. In effect, the prototypical Bcl-2 family
member, Bcl-2 was originally identiﬁed as an oncogene gene whose
expression was increased in most follicular lymphomas due to a
reciprocal chromosomal translocation (t14; 18) [194,195]. Over-
expression studies revealed that Bcl-2 was an atypical oncogene since
it did not serve to promote growth instead it was found to prevent cell
death in response to different stresses. These studies served as a
prelude to the development of our understanding of the central
importance of the different pro- and anti-apoptotic members of the
Bcl-2 family in the regulation of cell death [74].
A variety of other alterations that lead to increased resistance to
apoptosis has been described in different cancer cells [4,34,35,43,45].
These include a decrease in the expression of pro-apoptotic genes
such as Bax as well as decreased signaling from death receptors.
Nevertheless, the up-regulation of anti-apoptotic genes is likely the
most commonly reported mechanism used to evade apoptosis. The
genes identiﬁed to be up-regulated include the commonly observed
anti-apoptotic genes such as Bcl-2 and c-FLIP. Other common anti-
apoptotic genes that have been shown to be ubiquitously up-
regulated include a variety of heat shock proteins and chaperones as
well as genes encoding scavengers of reactive oxygen species (ROS)
[4,46,60,196]. Characterization of genes up-regulated in cancer cells
has also served and will likely continue to serve to identify many
novel anti-apoptotic genes [142,145,146,148,197]. For example,
Abtraham et al. [142] identiﬁed a number of up-regulated genes in
HeLa cells. Of these, metalloproteinase 15 (MMP-15) was chosen for
further study and it was shown that it prevented apoptosis when
overexpressed in both HeLa and human lung adenocarcinoma. This
suggests that in addition to its potential to promote tumor invasion inits role as an extracellular matrix proteinase, MMP-15 may also be
involved in oncogenesis as an anti-apoptotic gene. The realization of
the importance of the increased expression of many different anti-
apoptotic genes in mediating the process of tumorigenesis has lead to
development of pharmacological strategies in order to target these
proteins as adjuvants to enhance the effects of existing therapeutics
[44,126,127,133,134].
Anti-apoptotic phenotypes of tumor cells are developed in
response to the stressful microenvironments, that include limitations
on nutrients and oxygen availability, in which they develop
[46,158,198]. These stresses are similar to the effects that sublethal
levels of stresses have on all cells and are reminiscent to what occurs
in response to pre-conditioning. Similar types of phenotypic changes
occur in cancer cells that develop resistance to chemotherapeutic
agents. For example, gene chip screens identiﬁed cell survival or anti-
apoptotic genes as a major class of genes up-regulated in numerous
cells that develop resistance to a multitude of chemotherapeutic
agents including resistance to histone deacytylase inhibitors in colon
cancer cell lines [44,145,148,199].
3.3. Synaptic activity and other neuronal processes
Neuronal activity serves to promote cell survival, at least in part,
through the activation of neurotransmitter N-methyl-D-aspartate
(NMDA) glutamate receptors [200]. The neuronal calcium transients
elicited by the stimulation of NMDA calcium-permeable ion channels
serves to activate a survival program that has similarities to the
processes observed in pre-conditioning. Physiological, pharmacolog-
ical as well as gene chip experiments indicate that early NMDA
mediated cytoprotection involves activation of survival proteins like
kinases while longer lasting cytoprotection involves the up-regulation
of anti-apoptotic genes and the down regulation of pro-apoptotic
genes. Recent papers by Bading's group has used gene chips to identify
hundreds of genes that are differential expressed in response to NMDA
stimulation or synaptic activity in cultured hippocampal neurons
obtained from newbornmice [143,144]. Further, functional analysis of
a subset of these genes served to identify Bcl6 and Btg2 as novel
neuronal survival genes. A number of other up-regulated genes,
including many that are categorized as Activity-regulated Inhibitor of
Death (AID) genes, await further analysis. The increased synaptic
activity observed in these kinds of studies is related to the formation of
newneuronal connections that occurs during synaptic plasticity. These
results suggest that stimulation of endogenous anti-apoptotic path-
ways may also have therapeutic potential in limiting apoptosis in
neurological degenerative diseases such as Alzheimer's, Parkinson's or
stroke [41,55,201]. The concept of invoking anti-apoptotic processes
has also been explored for a number of other neurological diseases
such as glaucoma [202]. Glaucoma is a neuro-ophthalmological
disease that is a common cause of blindness that occurs because of
inappropriate apoptosis of retinal ganglion cells (RGC). Although
intraocular pressure (IOP) is a common risk factor, the exact PCD
trigger remains largely unknown [203]. Nevertheless, the loss of
trophic support is a likely factor given that neurotrophic agonists such
as BrainDerivedNeurotrophic Factor (BDNF) can play a protective role
[203]. As all other cells examined, RGC's are capable of mounting pre-
conditioned like protective defense mechanisms in response to mild
stress. In RGC's, the expression of a number of potential anti-apoptotic
genes is increased in response to different forms of stress [204]. One
such gene heat shock protein 27 (hsp27) is induced by a variety of
stresses including ischemic pre-conditioning [205]. In addition, its
overexpression has been shown to increase resistance to stress
mediated cell death in cultured rat ganglion cells [206]. This brings
up the concept, which we will discuss in more detail later on (see
section 4.5), that the ability to exploit the endogenous anti-apoptotic
machinery to prevent stress mediated cell death is likely to be useful
strategy to treat a variety of neurological diseases with increased
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epilepsy, amyotrophic lateral sclerosis (ALS) [48,202,207–209].
A variety of other receptor agonists as well as other diffusible
agents such as the autocoid neuroprotectin 1 (NPD1) are also capable
of preventing apoptosis in neuronal cells [210]. NDP1 is produced in
by the action of the 15-lipoxygenase on the essential fatty acid
docosahexaenoic acid (DHA). Although the exact molecular targets of
NDP1 are not well known, it does exert profound neuroprotective
effects in response to multiple stresses including diseases states. In
addition, NDP1 production is increased in response to stresses like
oxidative stresses. These effects of NDP1 are illustrated in recent study
that demonstrated that NDP1 enhanced the survival of retinal
ganglion cells of animals that underwent optic nerve transection
[211]. The observations that endogenous levels of NDP1 as well as the
levels of 15-lipoxygenase gene expression were increased following
the optic nerve axotomy suggests that NDP1 levels are part of the
neuronal cells anti-apoptotic response.
3.4. Hypometabolic conditions
Many organisms go through a resting type phase that allows them
to survive prolonged periods of severe stresses. Well-studied
examples include hibernation as well as the phenomena of diapauses
[212–214]. The later process is used to describe numerous phenom-
ena such as the “dauer” stage in Caenorhabditis elegans, spore stages
seen in many protozoans such as yeast and slime mold, as well as the
pause that is observed in mammalian pre-implantation embryos
[214]. Hibernation on the other hand is seen in a range of organisms
but is probably best described as a “sleep-like” stupor observed in
numerous animal species including many mammals. These dormancy
stages allow for survival in stressful environmental conditions such as
extremes in temperature and long-term decreased availability of
nutrients including energy sources and water. Survival is enhanced by
physiological adaptations such as decreased metabolism that serve to
conserve energy as well as genetic adaptations that allows for the
activation of genes encoding freeze tolerant proteins. These environ-
mental stresses combined with the intracellular stresses that ensue
(i.e., increased accumulation of waste products) are sufﬁcient to
induce signiﬁcant cell death in the absence of stress adaptation.
Similarities between resistance to dormancy and to ischemia/
reperfusion have been noted [159,215,216]. In effect, as observed in
preconditioning mediated resistance to ischemia/reperfusion stress,
there is increased expression of anti-apoptotic genes in both animals
that are dormant and that are arousing from hibernation. Many of the
genes identiﬁed are ubiquitous such as HSPs, anti-oxidants and
mitogenic kinases. Mitogenic kinases including ERK1/2 are thought to
be anti-apoptotic by virtue of their ability to promote cellular
proliferation while other kinases such as Protein Kinases A and C
are sometimes pro- and sometimes anti-apoptotic [69]. Nevertheless
there are reports on the identiﬁcation of a variety of other genes of
unknown function that suggest that increasing our understanding of
the stress protective mechanism of hibernation will lead to the
elucidation of novel anti-apoptotic processes many of which may
have clinical value [216–220].
3.5. Global stress responses
In response to stress, cells have evolved defense mechanisms in
order to prevent, repair and generally mitigate damage [4,60,177].
One of the earliest described pro-survival processes, originally
identiﬁed as a global response to UV mediated DNA damage, was
the bacterial SOS response in E. coli [81,221]. The mechanisms by
which DNA damage is transduced into physiological and genetic
responses to counter the negative effects of the stress are elegant and
complex processes. Some of these are worthwhile discussing here in a
little detail since they may be the best-characterized stress responsivesystems and as such, they serve as models to develop our
understanding of similar global stress responsive systems in eukary-
otic cells [81]. In a simplistic way, the SOS system is in large part
dependent on the constitutively expressed LexA sequence speciﬁc
DNA binding transcriptional repressor. During normal growth, LexA is
bound to and represses the expression of a number of genes
containing a so-called SOS motif. Upon DNA damage, replication is
stopped at the area of damage and this allows the RecA protein to bind
to single stranded DNA that becomes exposed at the site of the stalled
replication forks. This serves to activate the protease activity of RecA
and together with other proteins, activated RecA assists in the
degradation of the LexA protein. The decrease in LexA levels leads to
transcriptional derepression and activation of the transcription of the
LexA repressed genes. Thus, there is an increase in the levels of the
expression of several genes, the products of which serve as the
coordinated survival response to the damaged DNA. In a analogous
fashion to DNA damage response, cells mount a global response to the
stress of heat shock, the Heat Shock Response (HSR), a process that is
largely mediated by an increase in the activation and synthesis of a
speciﬁc transcription activator (σ32 in bacteria and Heat Shock Factor,
HSF in eukaryotes) that occurs in response to the accumulation of
denatured andmisfolded proteins [60,177,222]. In the case of HSR, the
genes that are induced largely consist of Heat Shock Proteins (HSPs)
and proteases that act respectively as chaperones to assist in the
refolding and in the degradation of misfolded proteins. Depending on
the protein and the cellular context, misfolded proteins can be
targeted for degradation by the well-known 20S proteosome, the
lysosome or the autophagosome [178,223]. In bacteria, the DegP
protein, which is a member of the highly conserved HtrA (high
temperature requirement protein A) proteases, is an interesting
example. This protein is a crucial stress response protein that has both
chaperone and protease function and is thus involved in the
recognition and the degradation of misfolded proteins [224].
Activation of existing proteins and pathways combined with changes
in gene expression is a common theme that serves to mediate
immediate and long-term protective strategies in response to
multiple different stresses.
Similar, although more complex stress responsive processes are
present in eukaryotic cells. Global stress responsive pathways have
been shown for DNA damage, heat and cold shock, osmotic stress,
oxidative stress, mechanical stress, hypoxia, starvation (autophagy),
metabolic stress, the stress of unfolded proteins in the ER (Unfolded
Protein Response, UPR) as well as the stress of caused by pathogens
such as invading viruses [3,60,81,177]. There are a number of unique
processes that occur in response to speciﬁc stresses. For example,
osmotic stress brings about physiological changes to the levels of
osmolytes that serve to rectify the stress-mediated alterations. This
process has been well characterized in yeast and requires the
activation of a speciﬁc MAP kinase cascade (HOG pathway) [225].
These global stresses will lead to PCD, via the activation of the typical
pathways, if they are of sufﬁcient intensity. Thus the overexpression
of most common anti-apoptotic genes such as ROS scavengers and
heat shock proteins will typically serve to delay or prevent cell death
in response to global stresses [4,177,226].
3.6. Aging
Aging is a multifaceted progressive process that involves a gradual
decrease in an organism's function that serves to decrease viability and
to increase the risk of death [227]. Over the years, many hypotheses
have been devised to help explain the defects that accumulate during
the process of aging [228–232]. A central role for alterations in energy
metabolism as well as an increase in the accumulation of ROS and
subsequent increases in the accumulation of cellular damage have
served as a focus formuch research. As in apoptosis, these defects point
to the mitochondria as a central regulator of aging. Although it has
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that aging is caused by PCD at least in lower eukaryotes [57,233]. The
identiﬁcation of the yeast sir2 (silent information regulator 2) and its
functional counterparts in other species including the mammalian
orthologue SIRT1 (Sirtuin 1) as proteins that extend lifespan have
served to conﬁrm the evolutionary conservation of the aging process
[230,234]. The fact that SIRT1 can prevent apoptosis while other
mammalian anti-apoptotic genes may serve to extend lifespan also
strengthens the concept that aging mediated cell death is likely a
programmed cell death involving the apoptotic or necrotic machinery
[56,234,235]. In addition to SIRT1, there are a total of seven SIRT genes
that encode class III histone deacytylases [234]. These serve in a variety
of different cellular processes including senescence, aging, apoptosis,
proliferation and cell cycle regulation. The identiﬁcation of polyphe-
nols from different food sources such as resveratrol from red wine as
well as a decrease caloric intake (Calorie Restriction or CR) as
processes that can activate of sir2/SIRT1 has served as a central
theme and has also generated an enormous interest in aging/
pharmaceutical research [230,232]. In spite of these successes, the
search for regulators of the agingprocess continues [230]. For example,
a recent study identiﬁed lithocholic acid as an intracellular lipid as a
negative modulator of aging in yeast that could among other things
negatively regulate mitochondrial mediated cell death [236]. Other
intracellular modulators of aging include spermidine [235]. Activation
of the protective effects of autophagy appears to be the mechanism by
which some of these compounds including spermidine as well as
sirtulins delay aging [237,238].
An alternative approach to aging research is focused on the
differences that exist in the lifespan of different species [228]. Many
invertebrates such as mollusks as well as mammals such as certain
whale species can live hundreds of years [229,239]. Combined
genomics and physiological approaches with long-lived species may
yield clues as to the aging process. Research with some long-lived bat
and bird species has identiﬁed ROS as being of central importance
[231]. For example, the mitochondria of a long lived species of brown
bats appear to produce less ROS per unit oxygen consumed than other
similar but short lived animal species [240]. On the other hand,
resistance to ROS mediated damage is higher in some long-lived bird
species [241]. Overall, an understanding of the mechanisms that a cell
has evolved to prevent aging will certainly increase our understand-
ing of the regulatory mechanisms that serve to delay apoptosis.
4. Identiﬁcation of anti-apoptotic sequences
Analysis of global gene expression proﬁles in apoptotic resistant
cells has successfully identiﬁed a number of genes that are up-
regulated in different types of apoptotic resistant cells [53,197,242–
245]. Many of the genes identiﬁed in these experiments have known
anti-apoptotic properties such as Bcl-2, Hsp72 or Hsp90 indicating
that they may be directly implicated in the ability to evade apoptosis
[196]. Although a possible anti-apoptotic role cannot be deduced from
the sequences of many of the other up-regulated genes, it has been
speculated that many of these represent potentially novel anti-
apoptotic sequences. In spite of the fact that many new anti-apoptotic
genes have been identiﬁed by characterizing some of these up-
regulated genes, it nevertheless remains that there usually too many
genes shown to be upregulated by gene chip analysis to blindly
analyze every sequence for potential anti-apoptotic characteristics
[142–148,169]. For example, although MMP15 is an example of a
novel anti-apoptotic gene that was originally identiﬁed as being up-
regulated in a tumor cell line, the same study reported a number of
other up-regulated genes whose potential as anti-apoptotic regulators
has not been characterized [142].
Alternative approaches have been successful in identifying anti-
apoptotic genes. For example, the anti-apoptotic Bag protein was
identiﬁed as a Bcl-2 interacting protein using a two-hybrid interactionscreen that was subsequently found to enhance the pro-survival
effects of Bcl-2 [246]. In genetic systems such as yeast and C. elegans,
screening for mutants that show increased sensitivity to different
stresses have lead to the identiﬁcation of novel pro-survival genes
[213,247]. Although many of these genes are speciﬁc to the model
organisms, a large number of these have functionally conserved
orthologues in mammalian cells, and given the interchangeability of
many genes in these systems, it is likely that many will have the same
function in mammals [16,105,176]. Although identical genetic screens
cannot be carried out in mammalian cells, a number of approaches
such as using global siRNA screens have nevertheless been fruitful in
identifying apoptotic regulators [248–250].
4.1. Yeast as model system to identify novel mammalian anti-apoptotic
sequences
Yeast is a genetic system that has served to unravel as well as
identify genes involved in a number of basic processes such as cell
cycle control, aging (the red wine anti-aging compound resveratrol
was ﬁrst identiﬁed in yeast) as well as autophagy [21,237,251–254].
The insights provided by yeast in developing the framework for our
understanding of these and other basic cellular processes is
exempliﬁed by the fact that 2 yeast researchers (L. Hartwell for
work with Saccharomyces cerevisiae and P. Nurse for work with S.
pompei) were awarded the 2001 Nobel prize in medicine [254,255].
More recently yeast as well as most eukaryotic unicellular organisms
have been shown to undergo genetically encoded cell death that is
mechanistically similar to the process of mitochondrial PCD seen in
metazoans [16,256–261]. A large number of different studies over the
last ten or so years have served to demonstrate that the yeast S.
cerevisiae is a widely used and effective model to study apoptosis
[57,233,261,262]. Although yeast apoptosis was initially controversial,
its acceptance is now widespread [57,105,263–265]. Given that yeast
is such a powerful genetic system, dissecting out the process of PCD in
yeast is likely to lead to increases in our knowledge of PCD in much
the same way that yeast has served to increase our understanding of
other basic cellular processes. In effect, the similarity and the
functional interchangeability between many different yeast and
human genes is so common [176,255], it is not surprising that
mammalian genes identiﬁed as negative regulators of PCD in yeast
screens, are also anti-apoptotic when expressed in mammalian cells
[266–269]. Although yeast is emerging as a widely usedmodel largely
because of its amenability to genetic approaches, there are a number
of other systems that have been developed that provide novel
advantages for the study of cell death [59]. For example, studies of
crustacean models of cell death have revealed similarities as well as
differences in both pro- and anti-apoptotic processes [270]. For
example, some animals like shrimp appear to have enhanced ability to
tolerate viral infection by a process termed viral accommodation
[271]. Thus, further studies in other model systems will likely identify
novel anti-apoptotic processes.
Thus, the genetically tractable yeast provides an alternative
strategy to screen for and identify novel anti-apoptotic sequences. A
commonly used screening system involves the use of yeast strains
that conditionally express a cDNA for an active form of the
mammalian pro-apoptotic Bax [105,272–274]. Although yeast does
not contain Bcl-2-like proteins, the heterologous expression of pro-
apoptotic Bax or Bak in yeast serves to induce death in a process that is
mechanistically similar to what occurs in mammalian cells [75,274–
277]. Numerous groups have exploited the conditionally lethal Bax-
dependent phenotype as a system to screen heterologous cDNA
libraries and identi fy novel ant i-apoptot ic sequences
[101,109,110,266,268,272,278,279]. Many of the genes thus identiﬁed
have also served to shed light on the process of anti-apoptosis. For
example, the identiﬁcation of ROS scavenging proteins as suppressors
of the lethal effects of Bax expression clearly implicates the role of ROS
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like sphingomyelin synthase 1 (SMS1) [101], identiﬁed in such a
screen has been conﬁrmed in mammalian cells [100,138,280].
4.2. The repertoire of mammalian anti-apoptotic genes
The anti-apoptotic Bcl-2 is likely the most studied and potent anti-
apoptotic gene and it displays many of the characteristics of the ideal
anti-apoptotic gene [44,195]. Bcl-2 is ubiquitously and constitutively
expressed so that its inactivation results in enhanced cell death in
response to stimuli. It is up-regulated to prevent apoptosis under
many conditions that serve to enhance cell survival including the
stress that fast growing tumor cells must withstand. A commonly
occurring chromosomal translocation resulting in increased expres-
sion of Bcl-2 is present in many tumors [194]. Thus Bcl-2 is
responsible for one of the hallmarks or tumor formation in many
cancers, namely the ability to evade apoptosis [11,158]. Functionally,
it is well known as a suppressor of the pro-apoptotic Bcl-2 member
Bax. In spite of this, Bcl-2 is likely to have other anti-apoptotic
functions that are Bax independent [281]. In addition, Bcl-2 may be
one of the earliest anti-apoptotic genes described. In effect early
reports clearly identiﬁed that the oncogenic effects of Bcl-2 was due to
ability to prevent cell death and not due any growth promoting
properties [194]. Here wewill discuss the large of other anti-apoptotic
genes have now been described.
A comprehensive list of anti-apoptotic and cell survival genes is
difﬁcult to compile. An analysis of the results of searches of the
existing literature on Pubmed, using keywords including anti-
apoptosis and cell survival genes, revealed a multitude of papers
that describe over 150 different unique genes. In addition, there are
785 anti-apoptotic gene entries in the Gene Ontology database
(http://www.geneontology.org/). The later list is an over estimation
since it contains the same gene from multiple species as well as
certain amount of other types of redundancies such as the inclusion of
genes encoding matching receptor–ligand pairs. Both lists are
incomplete since they lack some anti-apoptotic type genes. This
later part reﬂects the lack of a commonly used gene ontology for pro-
survival genes as well as a few other problems such as the fact that
many anti-apoptotic genes are also reported to be both anti- and pro-
apoptotic genes. This later fact may reﬂect differences in the function
of alternatively spliced variants, in different members of the same
gene family as well as cell type speciﬁc differences. For example, the
mammalian gene encoding transforming growth factor-beta stimu-
lated clone-22 (TSC-22) is a leucine zipper containing protein that
serves as a transcription co-factor [282] and it has been reported to be
both pro- and anti-apoptotic [283–286]. The confusion is likely due, at
least in part that there are four different alternatively spliced TSC22
genes in both the mouse and human genomes [285,286]. Further
examples of genes with dual roles include ligands for certain G-
Protein Coupled Receptors (GPCRs) that bind more than one receptor
subtype. For example, adrenaline mediated stimulation of the β1- and
the β2-adrenergic receptors respectively lead to pro- and anti-
apoptotic responses [287]. What is nevertheless noteworthy is the
diversity in the function of the different anti-apoptotic and cell
survival genes. Depending on the classiﬁcation used, there at least 11
different functional categories that are represented. They include the
classical anti-apoptotic sequences such as Bcl-2, IAPs and cFLIP
[10,42,152,288], chaperones including those involved in the proper
folding of proteins after ER stress as well as a number of heat shock
proteins [196,289–291], the genes encoding anti-oxidant proteins or
free radical scavengers such as superoxide dismutase (SOD) [292–
294], a number of different types of receptors including GPCRs,
steroids, cytokines and receptor tyrosine kinases [65,71,200,295–
300], enzymes including a number of kinases such as ERK1/2 as well
as a varieties others such as sphingomyelin synthase and dUTPase
[100,101,113,156,280,301], integrins and gap junctions like connexins[302,303], mitochondrial proteins including proteins involved in
electron transport [268], a large number of different transcription
factors including FOXO and NFκB as well as other DNA and RNA
binding proteins some of which are involved in repairing DNA [304–
307], proteins involved in regulating protein translation such as the
eIF4G family member DPA5 [308] and a variety of bacterial and viral
proteins many of unknown function that can inhibit cell death in their
host [42,154,309].
Finally, there are a large number of anti-apoptotic genes that are
categorized as functionally unknown. Not only are themechanisms by
which they prevent apoptosis not known, their basic function in the
cell is often unknown. This is the case for the family of Gadd45 family
of three proteins. GADD45 (Growth Arrest and DNA Damage
inducible) are conserved genes that are inducible in response to
stress and that can serve both pro- and anti-apoptotic functions [310].
Many other proteins are like the family of proteins called BAG. These
represent a complex family of proteins that are conserved from yeast
to plants to man [183]. As described above, they were originally
identiﬁed as Bcl-2 interacting protein that had anti-apoptotic effects
when overexpressed. They are classiﬁed as chaperones but how they
function as anti-apoptotic proteins remains largely unknown. A recent
study suggests that at least one familymembermay be involved in the
UPR responses that protects from ER stress [311]. Another interesting
example of a functionally orphan anti-apoptotic sequence is the
human TMEM85 gene. It was originally shown to function as an anti-
apoptotic gene by preventing Bax and ROS mediated cell death in
yeast [312]. Although its function is still unknown, a recent study of
the yeast orthologue (YGL231c now ECM4) suggests that it is part of
multiprotein endoplasmic reticulum complex that appears to be
involved in regulating ER stress [313]. These results are consistent
with the previous observation that yeast cells lacking YGL231c are
more sensitive to the apoptotic inducing effects of the Parkinson's
associated α-synuclein [314]. In addition, the list of anti-apoptotic
genes is likely to continue to get larger. Some of these new genes will
come from the genes, that have been shown and that will likely be
shown in the future, to be up-regulated in apoptotic resistant cells
[142–148]. Other sources of novel anti-apoptotic genes will come
from genetic screens [248,249,315]. For example, a number of groups
have reported isolating multiple mammalian cDNA sequences that
can prevent Bax mediated cell death in yeast but have yet to
characterize most of these [101,266,268,272]. Thus, the examination
of known anti-apoptotic sequences serves to highlight the diversity of
the anti-apoptotic processes as well as illuminating the fact that
signiﬁcant gaps in our knowledge still exists.
4.3. siRNAs increase the repertoire of anti-apoptotic sequences
The traditional well known mechanisms controlling the levels of
protein produced from a gene involves a number of different
regulatory steps. These include processes that regulate the level of
transcription of the gene, post-transcriptional events such as
regulating the processing and the half life of the unprocessed and
mature mRNA, post-translational mechanisms that regulate the rate
of translation of the mRNA into protein as well as the half life of the
protein itself. One of the most recent additions to these regulatory
processes is RNA interference (RNAi) [316,317]. RNAi is a post-
transcriptional mechanism that involves the production of small RNA
molecules that are capable of binding to mRNA molecules and
inhibiting their translation and possibly, at least in some species,
enhancing the degradation of the mRNA. Although a great deal of
information has been uncovered regarding the production and the
processes involved in siRNAs, an in depth discussion is beyond our
scope here but more information can be obtained from the existing
reviews on the subject [318–320]. There appears to be over 700
different genome encoded siRNAs that are involved in regulating
hundreds of different genes [318]. Our understanding of their
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involved in regulating a multitude of cellular and physiological
processes including apoptosis and thus they behave as global
regulators. A well characterized example is miR21 [320,321]. The
levels of miR21 are increased in number of cancers and its anti-
apoptotic effects appear to be due to its ability to decrease the
expression oncogenes including pTEN and TPM1 [318]. In a more
recent study, miR21 was also identiﬁed as one 40 differentially
regulated miRs in the hearts of pre-conditioned rats. The ability to
downregulate or overexpress miR21 in vivo and in cultured
cardiomyocytes suggested that increases in miR21 levels is directly
involved in mediating the anti-apoptotic phenotype associated with
pre-conditioning [322]. Further studies suggested that the gene
encoding Programmed Cell Death 4 (PDCD4) may be the miR21
target in cardiac cells. Although the exact function of PDCD4 is not
known, it nevertheless induces apoptosis when overexpressed in
cultured cardiomyocytes [322]. Thus, a miT|R21 mediated decrease in
the expression of a pro-apoptotic gene like PDCD4 may lead to the
observed increase in cell survival. These as well as other types of
screens for miRs will have diverse impacts on our understanding of
the processes of anti-apoptosis. For example, Sheng et al. [315] carried
out a complex but elegant reverse suicide screen using a mouse
malignant glioma cell line engineered to survive if the expression of
the anti-apoptotic activating transcription factor 5 (ATF5) is down
regulated. They were thus able to determine that two kinase
pathways, RAS-MAP and PI3 kinases lead to increased ATF5
expression and a cytoprotective phenotype by mediating an increase
in the transcription of the anti-apoptotic MCL-1 gene.
4.4. Alternative splicing of anti-apoptotic genes
Alternative splicing is a common phenomenon of mammalian
genes that often leads to the production of more than one protein
from a single gene [323]. A recent investigation has suggested that
92–94% of human genes are alternatively spliced and that 86% of these
genes produce low abundance splice variants [324]. Our own studies
reﬂect this since we have shown that all four of the human Bax
suppressors that we have characterized from our screen of mamma-
lian cDNA libraries in yeast are encoded by complex alternatively
spliced genes [101,286,312,325]. One of the prominent members of
these genes encodes sphingomyelin synthase 1 (SMS1). SMS1 is likely
to be anti-apoptotic by virtue of its ability to use the pro-apoptotic
sphingolipid ceramide as a substrate as well as the fact that it
produces the growth promoting diacylglycerol (DAG) [326]. The
mouse SMS1 gene is composed of 12 exons that are alternatively
spliced to produce three different proteins [327]. The 363 residue
form of SMS1 is thought to be the enzymatically active protein while
the C-terminally truncated forms of the protein are lacking more than
half of the protein and appear unlikely to be active. This has number of
functional implications including the observation that many of the
proteins produced by alternative splicing lack a functional domain but
retain their ability to interact with and often serve to inactivate the
full-length functional protein. This type of alternative or regulated
splicing appears to be a commonly observed phenomenon for genes
encoding proteins that are involved in regulating stress and apoptosis
in mammalian as well as yeast cells [328–330]. For example, the
truncated form of the BH3 Bcl-2 member Nix, sNix, is anti-apoptotic
by virtue of its ability to bind to and inhibit the pro-apoptotic Nix
protein[331]. This serves to indicate that the repertoire of pro- and
anti-apoptotic proteins will also require a complex understanding of
the entire transcriptome and proteome [332,333].
4.5. Clinical implications of apoptosis
Disregulated apoptosis is involved in pathophysiologies of
numerous diseases and disease processes [1,17,191]. Cancer andauto-immune diseases are the classical examples but not the only
diseases where anti-apoptosis is increased. In contrast, an increase
in apoptosis or a decreased ability to carry out anti-apoptosis is a
prominent part of many diseases such as Alzheimer`s and
Parkinson`s as well a number of pathophysiological processes
such as ischemic strokes and heart attacks [8,41,55,334]. Although
disregulated apoptosis is not necessarily the trigger that initiates
many of these diseases, the ability to control apoptosis would likely
go a long way as functional therapies. Consequently, there are a
large number of studies that are trying to decipher the apoptotic
processes disregulated in speciﬁc diseases as well as developing
drugs that can block speciﬁc or general pro- and anti-apoptotic
proteins and processes [34,41,50,55,198,335,336]. For example,
decreasing the levels of the mRNA for the anti-apoptotic galectin-3
gene using siRNA increased the sensitivity of tumor cells to the
death inducing effects of two different routinely used chemother-
apeutic drugs cisplatin and 5-ﬂuorouracil [122].
Given that caspases are key mediators of the cellular damage
that occurs during apoptosis, it is not surprising that they have
attracted a great deal of attention as potential drug targets [337]. In
spite of the fact that caspase inhibitors exist, they have nevertheless
been reported to have a limited ability to prevent cell death in
different pathophysiologies [40,41,337,338]. This observation is
consistent with the idea that in addition to caspase dependant
apoptosis, cells have a multitude of different genetically
programmed ways of killing themselves (i.e. autophagic and
necrotic programmed cell death (PCD)) especially when apoptosis
is blocked [25,338–342]. Thus a cell that faces conditions requiring
suicide can do so in caspase dependant or independent manner
[262,338]. Caspase independent processes leading to apoptosis can
be mediated, at least in some circumstances, by the release form the
mitochondria of pro-apoptotic proteins such as Endonuclease G
(Endo G) and Apoptosis Inducing Factor (AIF) [15]. When
endonuclease G is released from the mitochondria, it migrates to
the nucleus and catalyzes nuclear DNA cleavage in stressed cells.
AIF is a mitochondrially localized NADH oxidase that is also
released due to the mitochondrial membrane permeabilization in
stressed cells. Cellular damage is then mediated by cytosolic and
nuclear localized AIF. Similar to what is observed with caspase
inhibitors, anti-oxidant agents, which are known to prevent ROS
mediated cell death in cultured systems, are not as effective in
preventing cell death in the whole animal [40]. In contrast, the
overexpression of a number of anti-apoptotic genes, including
genes coding for caspase inhibitors such as IAPs and anti-oxidants
proteins, leads to decreased cell death following ischemic/reperfu-
sion injury or other pro-apoptotic situations in the heart and brain
[41,97,98,135–137,163,343–345]. This is in line with the observa-
tion that anti-apoptotic genes are more anti-death genes that are
capable of blocking caspase dependant and independent pathways
[40]. It is thought that strategies that serve to mimic naturally
occurring “anti-apoptotic” states are likely to have a greater clinical
efﬁciency than drugs that inhibit pro-apoptotic proteins
[4,40,41,48,346,347]. Thus strategies and methodologies are cur-
rently being developed that would promote increased levels of
these anti-apoptotic sequences either by injecting recombinant
proteins that can cross a cell's lipid bilayer and remain functional
[40,50,348–351] or by injection of a cDNA (naked or viral) that can
be taken up and expressed in the cell to make the anti-apoptotic
protein [40,352,353]. The expression of such proteins in tissues
such as heart is likely to be transient but this would be sufﬁcient
since anti-apoptotic protection would only be required for limited
times after an ischemic/reperfusion event.
A further proof of the usefulness of anti-apoptotic genes to prevent
apoptosis is provided by the biotechnology and pharmaceutical
industries. Mammalian cell lines are routinely used to produce a
variety of biopharmaceutical products such as recombinant proteins
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generates a multitude of environmental and intracellular stresses
that serves to induce apoptosis. For many years, cell lines that
overexpress a variety of different anti-apoptotic genes such as Bcl-2,
XIAP and Hsp72, have been generated in order to limit apoptotic cell
death and to increase the yield of products produced [47]. The ability
to limit apoptosis is also of interest in other biotechnologically
important cells such as yeast [354].
5. Autophagy and autophagic death
The processes and regulatory mechanisms by which cells actually
commit themselves to cellular suicide are not as cut and dried as
described above. The cell has also evolved a multitude of other
pathways that can be used to promote cell killing under appropriate
conditions. The complexity and the cooperative nature of the cell
death processes are apparent in Bax/Bak double knock out MEF cells
[340–342]. Although these cells are unable to activate the normal pro-
apoptotic cell death pathway, they will nevertheless undergo cell
death using alternative pathways in response to appropriate stimuli.
Early studies indicated that the death of Bax/Bak double knock out
cells following apoptosis inducing stimuli was likely due to the
activation of an autophagic process. Thus, the death was associated
with autophagosomes and could be inhibited by chemicals inhibitors
of autophagy and it was shown to be dependant of the autophagic
genes APG5 and Beclin [342]. More recently, it was shown that ER
stress mediated cell death in Bax/Bak double knock out cells was
delayed but it appeared to occur via a process that had similarities to
necrosis [341]. Autophagy was shown to be activated in response to
ER stress in both wild type and Bax/Bak double knock out cells. In wild
type cells, autophagy was protective since its inhibition served to
enhance ER stress mediated cell death. In contrast, inhibition of
autophagy served to protect Bax/Bak double knock out cells indicating
that autophagy is involved in mediating cell death.
Studies of regulated cell death have lead to the identiﬁcation of
three major types of genetically programmed cell death (PCD)
[1,8,355]. Type I PCD or apoptosis is the best-characterized form
while autophagic and necrotic cell deaths are classiﬁed respectively as
type II and III [1,18,356]. Although a great deal of information has been
uncovered regarding the different types of PCDs, many more
questions remain to be answered. One of the aspect that remains
largely unexplored in any systematic way is the fact that the diversity
in the processes involved in promoting PCD suggests that there also
exists a large number of different proteins that can prevent the
different “specialized” forms of apoptosis [38–41,346].
5.1. Autophagy protects from apoptosis
Autophagy, the process by which cells recycle cellular constitu-
ents, is a critical adaptation to starvation and plays an important role
in normal cell function and in PCD [21,23,24]. Our understanding of
autophagy was greatly accelerated by the identiﬁcation, by genetic
screening in yeast, of 30 or so conserved autophagic genes (ATG)
necessary for the process of autophagy [357]. Numerous studies have
since shown that these ATG genes function in a series of complex
interrelated signaling cascades that are involved in carrying out and
regulating autophagy [21]. At the macromolecular level, autophagy
involves the formation and subsequent engulfment of cellular
constituents destined to be recycled into structures called autopha-
gosomes. The mature autophagosomes fuse with lysosomes
(vacuoles in yeast) to make autophagolysosomes and the cellular
cargo is then degraded into building blocks for the synthesis of new
cellular contents or to be used for the energy requirements of the cell
[20,25]. Different forms of autophagy exist including many special-
ized forms such as microautophagy, mitophagy and chaperone
mediated autophagy [20,21,25]. These are mechanisms by whichcells can get rid of speciﬁc proteins or speciﬁc subcellular portions. It
is thought that constitutively low level of autophagy serves a general
housekeeping function to rid the cell of unwanted or damaged
material. Here we are more interested in macroautophagy that is
activated in times of starvation in order to recycle large amounts of
cellular material. This process is clearly of importance since blocking
autophagy, either genetically or pharmacologically, leads to rapid cell
death in response to starvation [21,358–360]. Autophagy has now
been shown to be up-regulated by and serve to protect cells from a
wide variety of other stresses including the stress encountered in
many diseases such as cardiac ischemia/reperfusion and cancer
[20,21,223,361–364]. One way autophagy can serve as an anti-
apoptotic process, is by removing mitochondria damaged by stress-
mediated increases in ROS (Reactive Oxygen Species) or activated
Bax before they get a chance to release their pro-apoptogenic factors
such as cytochrome c. The removal of other damaged cellular
components such as ER that contain an excess of unprocessed
proteins (ER stress) as well as other damaged components may also
serve to decrease general stress and prevent apoptosis [360]. The
ability to prevent aging mediated necrosis suggests that autophagy
may be capable of protecting from extreme stress [235,365,366].
More widespread anti-apoptotic roles for autophagy has been
suggested by a few recent studies [186,367–369]. One of these
important observations involves a potential link between autop-
hagy and pre-conditioning [22,369,370]. Pre-conditioning refers to
the cytoprotective effects that occur when cells are treated with
sub threshold and sublethal levels of an apoptotic stimulus
[52,162] (see Section 3.1). The up-regulation of different anti-
apoptotic genes, in a tissue speciﬁc manner, has for quite a while
been considered a satisfactory explanation for the effects of
preconditioning. More recent studies suggest that pre-conditioning
protects cells by an up-regulation of autophagy [22,369,370]. Of
similar potential far reaching importance for our understanding of
the process of anti-apoptosis is the observation that the cytopro-
tective effects of overexpressing anti-apoptotic genes may be due
to their ability to up-regulate autophagy [186,367,368]. A couple of
recent studies have suggested that some anti-apoptotic sequences
such as BAG1 and Hsp20 may function to prevent cell death by
activating autophagy. This makes a certain amount of inherent
logic given that the anti-apoptotic phenotype associated with pre-
conditioning is due, at least in part, to the up-regulation of anti-
apoptotic genes. It follows that many of the up-regulated anti-
apoptotic genes can prevent apoptosis when overexpressed. Since
the evidence that the anti-apoptotic phenotype of pre-conditioning
can also due to increased autophagy, it seems that the over-
expression of anti-apoptotic genes may be a common phenomena
responsible for this phenotype. The classical deﬁnition of an anti-
apoptotic sequence, that in addition to suppressing cell death
when overexpressed, cells must show an increased sensitivity to
apoptotic stimuli in cells lacking the gene. This is certainly the case
for many genes such as ROS scavengers and different heat shock
proteins [99,122–128]. These types of anti-apoptotic proteins are
likely to play a direct role in the cells anti-apoptotic repertoire. An
up-regulation of autophagy is also unlikely to be responsible for
the antagonist effects of other anti-apoptotic processes such as the
ability of Bcl2 to directly interfere with the pro-apoptotic function
of activated Bax [10]. On the other hand the up-regulation of
autophagy may account for other anti-apoptotic scenarios that
cannot be easily explained, such as the ability of Bcl-2 to protect
cells in a Bax independent manner [149,150]. These represent
exciting developments because an up-regulation of autophagy may
be a general mechanism by which the myriad of anti-apoptotic
genes, many of which with unknown function, serve to prevent cell
death. Such a scenario would explain how the deletion of some
anti-apoptotic genes does not lead to increased sensitivity to
apoptotic inducing stimuli, although it should be noted that other
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pathway may be a simpler explanation. Nevertheless, the concept
that autophagy is central to the process of anti-apoptosis is in line
with the complex cross talk that is already known to occur
between the different PCDs [281,339,355,356,371].
5.2. Autophagic mediated cell death
Type II PCD was coined autophagic cell death since the typical
markers of apoptosis were absent and numerous autophagosomes
were observed in the dying cells. Although there is a great deal of
evidence that autophagy can lead to cell death, there is now a growing
movement that is re-evaluating how strong is the evidence for the
widespread occurrence of autophagic cell death [25]. One of the
strongest examples in support of this challenge comes from inhibitory
studies. The cytoprotective role of autophagy is easily demonstratedFig. 3. Autophagy or type II PCD. Nutrient depletion mediated activation of TOR (Target of R
simplest form, autophagy is best known as a complex cellular process that is activated in res
order to promote survival. A great deal of evidence is accumulating that this form of autoph
serve as the central cellular control site to prevent premature or inadvertent cell death fro
prolonged autophagy as well as in other circumstances such as when type I PCD is blockedin response tomany stresses since the inhibition of autophagy leads to
enhanced cell death [21]. Therefore, it is argued that blocking
autophagy should enhance cell survival in cells undergoing type II
autophagic cell death [25,365]. The inability to prevent cell death by
blocking autophagy may be due to several factors including the
number of limited studies that have addressed the issue as well as the
fact that pharmacological inhibitors used to block autophagy are
rather non-speciﬁc. In addition, most genetic approaches used in
mammalian cells involve siRNAs and that such knockdowns of anti-
autophagic genes may not be sufﬁcient to prevent autophagy
[25,372–374]. The ease by which strains having knockouts of
autophagic genes can be used facilitates our ability to address these
and other questions in yeast [57,235,375].
Differing opinions regarding a potential role for autophagy in
autophagic type PCD remains given that there are a number of other
examples that argue for the importance of autophagic cell deathapamycin) is the best characterized mechanism that serves to activate autophagy. In its
ponse to the stress of nutrient deprivation that serves to recycle cellular constituents in
agy is activated by many mild forms of stresses, including pre-conditioning, in order to
m all three PCD processes. Type II PCD or autophagic cell death can occur in response
(not shown, see text for details).
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response to apoptotic stimuli in cells that are unable to carry out
apoptosis due to pharmacological inhibition or due to speciﬁc gene
knockouts (double Bak and Bax KOs) [25,342,377]. Thus it is argued
that autophagic cell death is an important backup mechanism to
ensure cell death is carried out. The consensus seems to suggest that
autophagy is protective at ﬁrst but death is observed in cells
subjected to prolonged stress that results in prolonged activation of
autophagy [378–380] (Fig. 3). It remains to be determined if
autophagic death following prolonged stress is due to cellular
exhaustion and/or depletion of cellular components or if it is due to
the activation of a speciﬁc PCD mechanism that serves to actively kill
cells. Our preliminary results, favours the later since we have
identiﬁed a human sequence that was found as a Bax suppressor in
yeast that can prevent cell death in response to prolonged periods of
starvation in yeast or when autophagy is activated with the TOR
inhibitor rapamycin [381]. The observation that cell death could be
delayed with a speciﬁc gene suggests that autophagic cell death is a
genetic process that is regulated and not simply a death brought
upon by exhaustion. The fact that we could not prevent autophagic
cell death with all of our Bax suppressors suggests that autophagic
cell death does not function by activating common apoptotic
pathways. The similarities, differences and cross-talk between
autophagic and apoptotic cell death is a current topic of high interest
[17,191,339,355,356,382].
5.3. Clinical implications
The growing realization of the importance of autophagy in the
physiological responses to stresses as well as its importance in
pathophysiological processes such as cancer, neurological and
cardiovascular diseases is quite obvious from the shear number of
reviews published in the ﬁrst half of 2010 [20,26,237,238,355,383–
405]. In cancer it is noteworthy that many autophagic genes are
tumor suppressors while a large number of others function as
oncogenes. Basal autophagy is thought to function to inhibit the
development of tumours while increased autophagy is seen in
tumours cells that are stressed because of treatments with
chemotherapeutics [362,380,406]. Thus autophagic inhibitors are
currently being used and many more are being developed to serveFig. 4. Necrosis or type III PCD. A genetically encoded form of necrosis is recognized as a form
in conditions of acute stress such as the severe ischemia that occurs following a stroke. This le
of type III PCD. Some intracellular processes such as the accumulation of unfolded proteins
activate type I PCD by mediating an increase in the release of calcium (Ca+2) that can caus
increase in calcium can also serve as the mediator of cross-talk since it can also activate t
apoptosis, may also lead to cell death by necroptosis via the RIP3 complex./RIP3 complex.as adjuvants to chemotherapeutics [362,380,406]. In contrast,
activation of autophagy in response to stresses such as ischemia
may promote cardiac cell survival and thus the development of
compounds capable of enhancing autophagy is of interest. The most
striking illustration of the potential and far reaching importance of
autophagy is the fact that a decrease in aging mediated cell death is
observed upon autophagy induction in all species examined so far
including yeast, worms, ﬂies, mice and primates [227,235,366].
Thus the identiﬁcation of novel targets involved in regulating
autophagy and autophagic cell death will increase our knowledge of
PCDs and may lead to increase therapeutic targets [223,336].
6. Necrotic death
Necrosis or type III PCD is the cell death that is observed in
response to severe stresses such that occurs after physical injury or
prolonged ischemia [1,2,18]. In fact excessive amount of most
apoptotic inducing stimuli will lead to necrosis. Thus, it is common
for dose dependant response to apoptotic stimuli to serve to identify
sublethal, apoptotic inducing as well supralethal or necrosis inducing
levels of stimuli. The mechanisms responsible for triggering necrosis
have traditionally received little attention because it was thought to
be just a physical process that was not regulated. Evidence is
accumulating that strongly suggests that necrosis can be regulated
and can occur as an alternative apoptotic independent genetically
encoded cell death pathway [18,30,249]. The term necroptosis has
been coined to differentiate the regulated form of necrosis from the
accidental type of cell necrotic death [338,407]. The identiﬁcation of
chemicals capable of inhibiting necroptosis as well as siRNAs involved
in regulating the process strongly suggests that in many cases the cell
death process is regulated [18,249,408]. Although necroptosis can
occur as part of normal physiological processes such as certain aspects
of development, it is common only in cells in which the normal
apoptotic pathway is blocked. Thus necroptosis, like autophagic cell
death, may serve the function of being a backup system for cellular
suicide if the main apoptotic pathway is defective [18,56]. Cross-
activation of autophagic (via activated calpain) and mitochondrial
(via increased Ca++) death pathways may also contribute to necrotic
cell death [33] (Fig. 4). Mechanistically, necroptosis is associated with
a depletion in ATP levels and increases in Ca++ levels from bothof type III PCD and is often called necroptosis. This process is most commonly observed
ads to a depletion in the levels of ATP which is one of the better characterized hallmarks
that lead to stress in the endoplasmic reticulum (ER, shown as red folds) also serve to
e mitochondrial damage and the release of pro-apoptogenic factors (not shown). The
ype III or necrotic PCD. Stimulation of TNF receptors, well known to induce extrinsic
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can lead to lysosomal rupture and the release and activation of
proteases such as cathepsins and cellular destruction. Necrotic cell
death has recently been shown to play an important role in cell death
associated with aging in yeast and mammalian cells [235,409].
Further, it was found that the addition of spermidine can protect
aged cells from necrotic death via a process involving the induction of
autophagy [235].
Clinically, necroptosis occurs in all tissue subjected to ischemia but
the process has received more attention with respect to ischemic
brain injury [33]. Areas of severe ischemia die by necrosis while less
severely affected cells undergo apoptotic cell death. It is thought that
the development of inhibitors of necrosis would have beneﬁcial
effects on stroke patients. In spite of the recent knowledge of
necroptosis, many questions remain including what are the mechan-
isms responsible for the rupture of the lysosome? Even though calpain
activation is associated with this event, there is no evidence that
blocking calpain will prevent rupture or necrosis. Identiﬁcation of
targets of calpain would be useful in further delineating the processes
involved in triggering necrosis. Some clues as to the mechanism(s)
mediating increases in the lability of the lysosomal membranes comes
from the observation that it is more prevalent following the
degradation of iron rich materials due to increase in redox active
iron within the lysosomes. The fact that intralysosomal chelation
agent desferrioxamine protects against cell death is consistent with
this concept [410]. Thus speciﬁc conditions may serve to prime the
cell for necrosis.
7. Alternative forms of programmed cell death
There are a number of other forms of PCD that have been
documented [36,191]. Many of these processes like anoikis (greek,
homelessness), mitotic catastrophe and pyroptosis (greek, ﬁre or
fever) were ﬁrst identiﬁed as being triggered by unique stimuli,
respectively as detachment of cells from their substratum (or from the
neighboring cells), premature entry into mitosis and infection by a
variety of organisms such as Salmonella [37,45,411]. Although there
are a number of unique features associated with these processes, such
as the activation of caspase 1 for pyroptosis, it remains to be
determined if any of these alternative processes are unique forms of
PCD or if they, like necroptosis (see above) represent subforms of the
existing types of PCD [36,191]. Nevertheless, studies of the mechan-
isms used to escape cell death from these other forms of PCD have
identiﬁed some novel mechanisms used to prevent cell death as well
as serving to develop therapeutic strategies for a number of
pathologies. For example, avoiding anoikis mediated cell death is a
common and likely necessary feature of tumor cells that are
undergoing metastasis [34,45]. Studies of metastasizing cells have
lead to the identiﬁcation of genes such as the focal adhesion protein
Talin1 and the neurotrophic receptor TrkB as anti-anoikis genes
[412,413]. On the other hand, bacteria and viruses have developed a
variety of strategies to prevent host mediated self-destruction
including activating the endogenous anti-apoptotic processes and
genes or by expressing their own anti-apoptotic genes [42,51]. Studies
with these kinds of inhibitors will be useful in delineating the unique
and common features of these types of PCDs.
8. Perspectives
The cellular mechanisms responsible for preventing cell death in
response to increasing stresses and to the activation of apoptotic
pathways represent complex and diverse mechanisms. Although our
understanding of anti-apoptosis has increased dramatically over the
last few years much remains to be elucidated. Nevertheless, a number
of recent developments clearly indicate that our ability to manipulate
the endogenous anti-apoptotic processes, as opposed to inhibitingapoptosis per se, will lead to functional therapies for a number of
diseases and pathophysiologies. Finally, one promising area of
research that has not been covered in this review is the emerging
importance of human embryonic stem cells. These cells can be used to
differentiate into a variety of specialized cell types and thus provide a
source of puriﬁed specialized cells that can be used to shed light on
cell type speciﬁc anti-apoptotic processes [414].
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